Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 7/20 | 0.55 |
| ▸ | HTR1B | P28222 | 6/20 | 0.52 |
| ▸ | HTR2A | P28223 | 5/20 | 0.48 |
| ▸ | HTR2C | P28335 | 2/20 | 0.48 |
| ▸ | HTR1A | P08908 | 3/20 | 0.45 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.45 |
| ▸ | MPO | P05164 | 3/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25903380 | 0.88 | HTR1D (0.69) | HTR1DHTR1BHTR2AHTR2CHTR1A | |
| SCHEMBL9210389 | 0.83 | HTR1D (0.51) | HTR1DHTR1BHTR2AHTR2CHTR1A | |
| SCHEMBL18854105 | 0.83 | HTR1D (0.51) | HTR1DHTR1BHTR2AHTR2CHTR1A | |
| SCHEMBL9200459 | 0.80 | HTR1D (0.49) | HTR1DHTR1BHTR2AHTR2CHTR1A | |
| SCHEMBL14555321 | 0.77 | ATM (0.47) | HTR1DHTR1BHTR2AHTR2CHTR1A | |
| SCHEMBL8297901 | 0.77 | GPR84 (0.73) | HTR2AHTR2CHTR1AGPR84MPO | |
| SCHEMBL28918253 | 0.76 | HTR1D (0.42) | HTR1DHTR1BHTR2AHTR2CHTR1A | |
| SCHEMBL14555351 | 0.76 | HTR1D (0.46) | HTR1DHTR1BHTR2AHTR2CGPR84 | |
| SCHEMBL22643951 | 0.75 | HTR1D (0.75) | HTR1DHTR1BHTR2AHTR1AMPO | |
| SCHEMBL12013054 | 0.75 | HTR1D (0.73) | HTR1DHTR1BHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10370358-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180194746-A1 | Compounds For the Treatment of HIV | GILEAD SCIENCES, INC. | 2018-07-12 | — | — | US | disclosed |
| EP-2729448-B1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES INC (US) | 2015-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10370358-B2 | Compounds for the treatment of HIV | CCR5, NPC1, FURIN | HTR1D 4753/4885HTR1B 4456/4885HTR2A 4866/4885 |
| US-20180194746-A1 | Compounds For the Treatment of HIV | CCR5, NPC1, FURIN | HTR1D 4753/4885HTR1B 4456/4885HTR2A 4866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.